GE To Accelerate Development Of Nanoparticle Based Imaging Agents To Diagnose Cancer And Heart Disease Earlier
Oct 1st 2008Drug InformationMRI / PET / Ultrasound
GE Global Research, the technology development arm for the General Electric Company (NYSE: GE), announced a two-year cooperative research and development agreement with the National Cancer Institute (NCI) to accelerate the development of cutting-edge nanoparticle based imaging agents that have the potential to revolutionize the diagnosis and treatment of cancer and heart disease.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
